These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 35687882)

  • 1. Effectiveness and Tolerability of Supratherapeutic Dosing of Vortioxetine in Patients With Treatment-Resistant Depression.
    Cuomo A; Santucci A; Chioccioli M; Goracci A; Bolognesi S; Fagiolini A
    Prim Care Companion CNS Disord; 2022 Jun; 24(3):. PubMed ID: 35687882
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study.
    De Carlo V; Vismara M; Grancini B; Benatti B; Bosi MF; Colombo A; Viganò CA; Dell'Osso B
    Hum Psychopharmacol; 2020 Sep; 35(5):e2750. PubMed ID: 32662933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders.
    Findling RL; Robb AS; DelBello MP; Huss M; McNamara NK; Sarkis EH; Scheffer RE; Poulsen LH; Chen G; Lemming OM; Auby P
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):47-54. PubMed ID: 29035574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.
    Zheng J; Wang Z; Li E
    Afr Health Sci; 2019 Mar; 19(1):1716-1726. PubMed ID: 31149002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A naturalistic, 24-week, open-label, add-on study of vortioxetine in bipolar depression.
    Siwek M; Chrobak AA; Sołtys Z; Dudek D; Krupa AJ; Rybakowski JK
    Psychiatr Pol; 2022 Jun; 56(3):509-522. PubMed ID: 36342982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial.
    Adamo D; Pecoraro G; Coppola N; Calabria E; Aria M; Mignogna M
    Oral Dis; 2021 May; 27(4):1022-1041. PubMed ID: 32790904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study.
    Thase ME; Jacobsen PL; Hanson E; Xu R; Tolkoff M; Murthy NV
    J Affect Disord; 2022 Apr; 303():123-130. PubMed ID: 35131363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA).
    Yang YK; Chen CS; Tsai CF; Chang CM; Lai TJ; Lee CT; Lin CC; Lan TH; Herr KJ
    Curr Med Res Opin; 2021 Dec; 37(12):2163-2173. PubMed ID: 34515596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis.
    Li Z; Liu S; Wu Q; Li J; Yang Q; Wang X; Peng P; Wang Q; Liu Y; Li M; Hao Y; Xu H; He L; Wang Y; Chen S; Liu T
    Int J Neuropsychopharmacol; 2023 Jun; 26(6):373-384. PubMed ID: 37105713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).
    Chin CN; Zain A; Hemrungrojn S; Ung EK; Kwansanit P; Au Yong KC; Chong MSW; Inpa C; Yen TH; Yeoh BBD; Tay LK; Bernardo C; Lim LC; Yap CH; Fones C; Nayak A; Nelleman L
    Curr Med Res Opin; 2018 Nov; 34(11):1975-1984. PubMed ID: 29768955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study.
    De Berardis D; Fornaro M; Anastasia A; Vellante F; Olivieri L; Rapini G; Serroni N; Orsolini L; Valchera A; Carano A; Tomasetti C; Ventriglio A; Bustini M; Pompili M; Serafini G; Perna G; Iasevoli F; Martinotti G; Di Giannantonio M
    Braz J Psychiatry; 2020; 42(3):317-321. PubMed ID: 32159712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Alam MY; Jacobsen PL; Chen Y; Serenko M; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2014 Jan; 29(1):36-44. PubMed ID: 24169027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial.
    Borhannejad F; Shariati B; Naderi S; Shalbafan M; Mortezaei A; Sahebolzamani E; Saeb A; Hosein Mortazavi S; Kamalzadeh L; Aqamolaei A; Ali Noorbala A; Namazi-Shabestari A; Akhondzadeh S
    J Clin Pharm Ther; 2020 Aug; 45(4):804-811. PubMed ID: 32420649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.